Université de Lorraine, CNRS, L2CM UMR 7053, F-54000 Nancy, France.
Université de Lorraine, CNRS, LPCT UMR 7019, F-54000 Nancy, France.
Dalton Trans. 2020 Aug 25;49(33):11451-11466. doi: 10.1039/d0dt02135k.
In this perspective, we discuss iron-complexes as drug candidates that are promising alternatives to conventional platinum-based chemotherapies owing to their broad range of reactivities and to the targeting of different biological systems. Breakthroughs in the comprehension of iron complexes' structure-activity relationship contributed to the clarification of their metabolization pathways, sub-cellular localization and influence on iron homeostasis, while enlightening the primary molecular targets of theses likely multi-target metallodrugs. Both the antiproliferative activity and elevated safety index observed among the family of iron complexes showed encouraging results as per their therapeutic potential and selectivity also with the aim of reducing chemotherapy side-effects, and facilitated more pre-clinical investigations. The purpose of this perspective is to summarize the recent advances that contributed in unveiling the intricate relationships between the structural modifications on iron-complexes and their reactivity, cellular trafficking and global mechanisms of action to broaden their use as anticancer drugs and advance to clinical evaluation.
在这篇观点文章中,我们讨论了铁复合物作为药物候选物,由于其广泛的反应性和针对不同生物系统的靶向性,它们是有前途的传统铂类化疗替代品。对铁复合物结构-活性关系的理解的突破有助于阐明其代谢途径、亚细胞定位和对铁稳态的影响,同时阐明这些可能的多靶标金属药物的主要分子靶点。铁复合物家族中观察到的增殖活性和升高的安全性指数表现出令人鼓舞的结果,因为它们具有治疗潜力和选择性,旨在降低化疗副作用,并促进更多的临床前研究。本文的目的是总结最近的进展,这些进展有助于揭示铁复合物的结构修饰与其反应性、细胞内转运和整体作用机制之间的复杂关系,以扩大它们作为抗癌药物的用途并推进临床评估。